Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test

Boston Scientific’s 2026 guidance cut undermines the timing of its recovery, with WATCHMAN sales weakness, EP share losses, and delayed margin improvement extending the rebound toward 2028. The update suggests earlier margin and earnings stabilization is slipping, increasing near-term execution risk. Overall, the company’s trajectory appears cautious as it works through product performance headwinds and profitability normalization.

Analysis

Boston Scientific’s 2026 guidance cut undermines the timing of its recovery, with WATCHMAN sales weakness, EP share losses, and delayed margin improvement extending the rebound toward 2028. The update suggests earlier margin and earnings stabilization is slipping, increasing near-term execution risk. Overall, the company’s trajectory appears cautious as it works through product performance headwinds and profitability normalization.